The site of inhibition of bacterial cell wall peptidoglycan synthesis by azureomycin B, a new antibiotic.
Azureomycin B (10 micrograms/ml), a new antibiotic from Pseudonocardia azurea nov. sp., caused the accumulation of lipid intermediate and inhibition of peptidoglycan synthesis in an invitro system using a particulate fraction from Bacillus megaterium KM with UDP-MurNAc-[3H]pentapeptide and cold UDP-GlcNac or cold UDP-MurNAc-pentapeptide and UDP-[3H]GlcNAc as substrates. At higher concentrations of azureomycin B (over 100 microgram/ml), lipid intermediate accumulation was also inhibited. When particulate fraction from Escherichia coli Y-10 and UDP-[14C[GlcNAc and cold UDP-MurNAc-pentapeptide were used, accumulation of lipid intermediate and inhibition of peptidoglycan synthesis were also observed. These results indicate that the primary target of azureomycin B is the transfer of the disaccharide peptide unit (GlcNAc-MurNAc-pentapeptide) from lipid-bound precursor to acceptor.
D000192:Actinomycetales; D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D001410:Bacillus megaterium / Q000378:metabolism*; D002473:Cell Wall / Q000378:metabolism*; D004926:Escherichia coli / Q000378:metabolism*; D010455:Peptides / Q000494:pharmacology*; D010457:Peptidoglycan / Q000096:biosynthesis*; D014537:Uridine Diphosphate N-Acetylglucosamine / Q000378:metabolism; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D010455:Peptides; D010457:Peptidoglycan; D014537:Uridine Diphosphate N-Acetylglucosamine; D014640:Vancomycin; C025267:azureomycin B